| Julia M Kerrigan, MD | |
|
1417 8th Ave, Bethlehem, PA 18018-2256 | |
| (484) 526-5210 | |
| (866) 568-6561 |
| Full Name | Julia M Kerrigan |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 14 Years |
| Location | 1417 8th Ave, Bethlehem, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225470537 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | MD465311 (Pennsylvania) | Primary |
| 2084N0400X | Psychiatry & Neurology - Neurology | A125784 (California) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| St Lukes Quakertown Hospital | Quakertown, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Luke's Physician Group Inc | 6709798333 | 1739 |
News Archive
Working with a national team of researchers, a scientist from the Florida campus of The Scripps Research Institute has shown for the first time a link between low levels of a specific hormone and increased risk of metabolic disease in humans.
Measles deaths fell from 733,000 in 2000 to 164,000 in 2008 - 78 percent - thanks, in part, to increased vaccination efforts that reached an estimated 700 million children, according to a report released Thursday by the U.S.-based Measles Initiative, Reuters reports.
Array BioPharma Inc. today announced the presentation of positive Phase 1 clinical data for its novel kinesin spindle protein inhibitor, ARRY-520. The data, which were presented at the 2010 Annual Meeting of the American Society of Hematology in Orlando, Florida, indicate that ARRY-520 was well tolerated and has shown encouraging preliminary results in the treatment of multiple myeloma.
Research continues to unveil potential benefits of omega-3 fatty acids found in seafood, pointing to healthful effects on the lungs in children, the uterus in women and hearing in older adults. The August 2010 PUFA Newsletter and Fats of Life e-newsletters for health professionals and consumers, respectively, report the latest findings about these and other topics.
AssureRx Health, Inc. today announced it has launched a personalized medicine test for the growing number of children and adults diagnosed with attention deficit hyperactivity disorder (ADHD). The new pharmacogenomic test can assist clinicians with important medication decisions that result from genomic differences in how individual patients tolerate ADHD medications.
› Verified 5 days ago
| Entity Name | St Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700984622 PECOS PAC ID: 6709798333 Enrollment ID: O20040226000062 |
News Archive
Working with a national team of researchers, a scientist from the Florida campus of The Scripps Research Institute has shown for the first time a link between low levels of a specific hormone and increased risk of metabolic disease in humans.
Measles deaths fell from 733,000 in 2000 to 164,000 in 2008 - 78 percent - thanks, in part, to increased vaccination efforts that reached an estimated 700 million children, according to a report released Thursday by the U.S.-based Measles Initiative, Reuters reports.
Array BioPharma Inc. today announced the presentation of positive Phase 1 clinical data for its novel kinesin spindle protein inhibitor, ARRY-520. The data, which were presented at the 2010 Annual Meeting of the American Society of Hematology in Orlando, Florida, indicate that ARRY-520 was well tolerated and has shown encouraging preliminary results in the treatment of multiple myeloma.
Research continues to unveil potential benefits of omega-3 fatty acids found in seafood, pointing to healthful effects on the lungs in children, the uterus in women and hearing in older adults. The August 2010 PUFA Newsletter and Fats of Life e-newsletters for health professionals and consumers, respectively, report the latest findings about these and other topics.
AssureRx Health, Inc. today announced it has launched a personalized medicine test for the growing number of children and adults diagnosed with attention deficit hyperactivity disorder (ADHD). The new pharmacogenomic test can assist clinicians with important medication decisions that result from genomic differences in how individual patients tolerate ADHD medications.
› Verified 5 days ago
| Entity Name | Gslpg, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366006702 PECOS PAC ID: 7810226875 Enrollment ID: O20190917001763 |
News Archive
Working with a national team of researchers, a scientist from the Florida campus of The Scripps Research Institute has shown for the first time a link between low levels of a specific hormone and increased risk of metabolic disease in humans.
Measles deaths fell from 733,000 in 2000 to 164,000 in 2008 - 78 percent - thanks, in part, to increased vaccination efforts that reached an estimated 700 million children, according to a report released Thursday by the U.S.-based Measles Initiative, Reuters reports.
Array BioPharma Inc. today announced the presentation of positive Phase 1 clinical data for its novel kinesin spindle protein inhibitor, ARRY-520. The data, which were presented at the 2010 Annual Meeting of the American Society of Hematology in Orlando, Florida, indicate that ARRY-520 was well tolerated and has shown encouraging preliminary results in the treatment of multiple myeloma.
Research continues to unveil potential benefits of omega-3 fatty acids found in seafood, pointing to healthful effects on the lungs in children, the uterus in women and hearing in older adults. The August 2010 PUFA Newsletter and Fats of Life e-newsletters for health professionals and consumers, respectively, report the latest findings about these and other topics.
AssureRx Health, Inc. today announced it has launched a personalized medicine test for the growing number of children and adults diagnosed with attention deficit hyperactivity disorder (ADHD). The new pharmacogenomic test can assist clinicians with important medication decisions that result from genomic differences in how individual patients tolerate ADHD medications.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Julia M Kerrigan, MD 1417 8th Ave, Bethlehem, PA 18018-2256 Ph: (484) 526-5210 | Julia M Kerrigan, MD 1417 8th Ave, Bethlehem, PA 18018-2256 Ph: (484) 526-5210 |
News Archive
Working with a national team of researchers, a scientist from the Florida campus of The Scripps Research Institute has shown for the first time a link between low levels of a specific hormone and increased risk of metabolic disease in humans.
Measles deaths fell from 733,000 in 2000 to 164,000 in 2008 - 78 percent - thanks, in part, to increased vaccination efforts that reached an estimated 700 million children, according to a report released Thursday by the U.S.-based Measles Initiative, Reuters reports.
Array BioPharma Inc. today announced the presentation of positive Phase 1 clinical data for its novel kinesin spindle protein inhibitor, ARRY-520. The data, which were presented at the 2010 Annual Meeting of the American Society of Hematology in Orlando, Florida, indicate that ARRY-520 was well tolerated and has shown encouraging preliminary results in the treatment of multiple myeloma.
Research continues to unveil potential benefits of omega-3 fatty acids found in seafood, pointing to healthful effects on the lungs in children, the uterus in women and hearing in older adults. The August 2010 PUFA Newsletter and Fats of Life e-newsletters for health professionals and consumers, respectively, report the latest findings about these and other topics.
AssureRx Health, Inc. today announced it has launched a personalized medicine test for the growing number of children and adults diagnosed with attention deficit hyperactivity disorder (ADHD). The new pharmacogenomic test can assist clinicians with important medication decisions that result from genomic differences in how individual patients tolerate ADHD medications.
› Verified 5 days ago
Edgar M Vizcaino, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 865 E 4th St, Bethlehem, PA 18015 Phone: 484-221-9136 Fax: 484-221-9130 | |
Dr. Sandra Wandji Veigne, M.D Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 801 Ostrum St, Bethlehem, PA 18015 Phone: 484-822-5700 | |
Dr. Jonathan P. Hosey, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1417 8th Ave, Bethlehem, PA 18018 Phone: 484-526-5210 Fax: 484-526-5237 | |
Itay Keshet, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2545 Schoenersville Rd, Bethlehem, PA 18017 Phone: 484-884-2888 Fax: 484-884-2885 | |
Brian Hanrahan, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1417 8th Ave, Bethlehem, PA 18018 Phone: 484-526-5210 | |
Laurence P Karper, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2545 Schoenersville Rd, 5th Floor Lvh-m South, Bethlehem, PA 18017 Phone: 484-884-6503 Fax: 484-884-6504 | |
Rekha Srinivasan, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2710 Schoenersville Rd, Bethlehem, PA 18017 Phone: 610-297-7500 Fax: 610-297-7533 |